The American Medical Association (AMA) has published two new documents designed to help physicians affected by the ongoing COVID-19 pandemic.

Healthcare providers should use caution when considering the treatment of COVID-19 patients with hydroxychloroquine and azithromycin if the patients have cardiovascular disease.

One side effect of this unprecedented time is that many fourth-year medical students are being asked to join the pandemic’s front lines before they have even graduated.

Leading healthcare societies have penned a letter to CMS Administrator Seema Verma asking for Medicare Advantage plans to waive prior authorization requirements during the ongoing COVID-19 pandemic.

Healthcare workers throughout the country have reported being unable to find the necessary ventilators, test kits and personal protective equipment (PPE) needed to care for patients affected by this ongoing pandemic.

The American College of Cardiology and American Heart Association reached the same conclusion in 2019.

Healthcare conferences all over the world have been delayed or canceled due to the COVID-19 pandemic, and two more significant cancellations have been announced that impact cardiology professionals.

The American Heart Association (AHA) has set aside $2.5 million to fund cardiovascular and cerebrovascular research into the new coronavirus.